Search results
Results from the WOW.Com Content Network
Sulfonylureas have a greater risk of hypoglycemia but the risk is still only around 3% of patients who use them. [35] In patients who have a greater risk of low sugar, such as in the elderly and patients with kidney disease, the starting dose can be as low as 0.5 mg.
As a result, there has been difficulty in developing guidelines on interpretation and treatment of low blood glucose in neonates aged less than 48 hours. [8] Following a data review, the Pediatric Endocrine Society concluded that neonates aged less than 48 hours begin to respond to hypoglycemia at serum glucose levels of 55–65 mg/dL (3.0–3. ...
Nephrology Section: Joslin provides the educational, medical, and emotional support needed to manage all forms of kidney disease, which impacts a significant number of people with diabetes. The goal is to detect, delay, and potentially reverse the effects of diabetes on the kidneys as early as possible.
Since repeated hypoglycemia is common in people with diabetes who strive to keep their glucose levels near normal, the incidence of hypoglycemic unawareness becomes more prevalent in patients who follow 'intensive treatment' protocols. The most common treatment for this condition is to liberalize the patient's target glucose levels, in an ...
Intensive insulin therapy or flexible insulin therapy is a therapeutic regimen for diabetes mellitus treatment. This newer approach contrasts with conventional insulin therapy. Rather than minimize the number of insulin injections per day (a technique which demands a rigid schedule for food and activities), the intensive approach favors ...
Pediatric endocrinologists are usually the primary physicians involved in the medical care of infants and children with intersex disorders. The specialty also deals with hypoglycemia and other forms of hyperglycemia in childhood, variations of puberty, as well other adrenal, thyroid, and pituitary problems.
Type 1 diabetes is a disease caused by the lack of insulin. Thus, insulin is the main treatment agent for type 1 and is typically administered via subcutaneous injection. Type 2 diabetes is a disease of insulin resistance by cells. Type 2 diabetes is the most common type of diabetes.
Fasting hypoglycemia is often the most significant problem in GSD I, and typically the problem that leads to the diagnosis. Chronic hypoglycemia produces secondary metabolic adaptations, including chronically low insulin levels and high levels of glucagon and cortisol. Lactic acidosis arises from impairment of gluconeogenesis.